INSTRUMENT: POR-FESR 2014-2020 – Call: Programma di ricerca e sviluppo per l’integrazione della filiera BIOMED
TITLE: INibitori di CDK Innovativi per il Tumore al pancrEas (INCITE) – Innovative CDK Inhibitors for the Treatment of Pancreatic Cancer
Pancreatic cancer has not yet an adequate treatment and is rated among the most aggressive cancers, with 26.611 new cases in Europe every year, ranking as the 7th leading cause of cancer death in both sexes (over 74% of patients do not survive at 1 year since diagnosis and 95% dies within 5 years).CDK4/6 is an important and actionable target in pancreatic cancer. Furthermore, CDK9 represents a good target in pancreatic cancer as its inhibition can synergize with DNA damaging agents.
ViroStatics established a collaboration with the leading center of the University of Verona, Italy (AOUI, led by prof. Tortora and colleagues), bearing more than 40 years’ experience in the field of pancreatic diseases. Our colleagues have established that ViroStatics’ lead candidate VS2-370 is potent against cell lines from pancreatic cancer, more potent than other drugs currently approved for the treatment of pancreatic cancer or in advanced stage of development. VS2-370 could be used in combination with paclitaxel, GDC0068, LY2090314, SN-38, all treatment options in this setting with which VS2-370 showed synergistic activity in inhibiting tumour growth.
This project successfully concluded in April 2019.
INSTRUMENT: POR FESR 2014-2020 “Innovation Services” – Project CUP G83D1600010002
TITLE: Servizi per l’Innovazione
This project aimed at characterizing the mechanism of action of ViroStatics’ library of compounds with mainly proteomics analysis. These studies have been implemented in collaboration with Porto Conte Ricerche.
Project timeline: Jan 2016-Sep 2016